NEW YORK (GenomeWeb) – Xagenic today announced it has acquired exclusive rights to a mutation detection technology developed at the University of Toronto that could be used in liquid biopsy testing.

The electrochemical clamp assay technology detects specific SNPs and genetic mutations in cell-free nucleic acids in blood plasma or serum. Xagenic said the acquisition could enable the Xagenic X1 platform to expand into blood-based or liquid biopsy testing.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.